Case Studies

INTERACT2 – A Large Scale Clinical Trial in Stroke

George Clinical, a leading Asia-Pacific CRO, is wholly owned by The George Institute, a world leading medical research institute focused on chronic disease. Our model sees us forming integrated project teams with our scientific thought leaders. The Neurological & Mental Health unit, one of the many divisions within The George Institute, has led many clinical […]

Read More

May 27th, 2014

Proving salt reduction reduces stroke and mortality

Effective management of diseases such as hypertension requires more than drug therapy, but also a change in diet and lifestyle.

Read More

March 14th, 2014

PROGRESS, the largest clinical trial for secondary prevention of stroke

A randomised, double-blind trial examining the effects of an ACE inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease.

Read More

January 15th, 2014

SAFE, the largest clinical trial in critical care medicine

A randomised controlled double-blind study comparing the effects of saline versus albumin on mortality in 6,997 patients, with up to 30 days of follow-up. Saline vs Albumin Read more about the SAFE trial on The George Institute website This trial was completed under budget and ahead of schedule, with results published in The New England […]

Read More

January 15th, 2014

ADVANCE, the largest clinical trial in diabetes

Action in Diabetes Read more about the ADVANCE trial on The George Institute website A factorial, randomised controlled trial study designed to determine the effects of intensive blood pressure lowering and glucose control on cardiovascular risks among type 2 diabetes patients. Covering both advanced economies in North America and Western Europe and emerging economies in […]

Read More

January 15th, 2014

Too busy for a healthy lifestyle?

As active contributors in research, sometimes it’s nice to take a step back and reflect how our work evolves from novel treatment to everyday practice.

Read More

January 7th, 2014

Strong evidence for use of dual antiplatelet therapy in ‘mini-strokes’

Evidence is increasing of the benefits, without increased risks, of using dual antiplatelet therapy – aspirin and clopidogrel – as soon as possible and continued for up to 3-months in patients with minor acute ischaemic stroke or transient ischaemic stroke (TIA), so-called mini-strokes. The evidence is derived from multiple randomised controlled trials, including a recent […]

Read More

September 19th, 2013

Benefits of DPPIV-inhibitors still uncertain

The recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]

Read More

September 17th, 2013

New treatment for the most serious form of stroke

Intracerebral hemorrhage is the most serious form of stroke with high rates of mortality and a low chance of recovery to functional independence. In Asia-Pacific, it affects more than one million people annually, kills one third of them and leaves most survivors with disability. For reasons yet unknown, intracerebral hemorrhage is also more prevalent in […]

Read More

August 6th, 2013
Older Indian man smoking

COPD and its co-morbidities

COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia-Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated to […]

Read More

August 6th, 2013

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network